Andriy Moshyk

4.1k total citations
50 papers, 313 citations indexed

About

Andriy Moshyk is a scholar working on Oncology, Molecular Biology and Economics and Econometrics. According to data from OpenAlex, Andriy Moshyk has authored 50 papers receiving a total of 313 indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Oncology, 12 papers in Molecular Biology and 11 papers in Economics and Econometrics. Recurrent topics in Andriy Moshyk's work include Cancer Immunotherapy and Biomarkers (29 papers), CAR-T cell therapy research (25 papers) and Cutaneous Melanoma Detection and Management (13 papers). Andriy Moshyk is often cited by papers focused on Cancer Immunotherapy and Biomarkers (29 papers), CAR-T cell therapy research (25 papers) and Cutaneous Melanoma Detection and Management (13 papers). Andriy Moshyk collaborates with scholars based in United States, United Kingdom and Germany. Andriy Moshyk's co-authors include Srividya Kotapati, Marie Tournier, Amir Abbas Tahami Monfared, Thiérry Ducruet, Yola Moride, Andrew Grant, Helen M. Johnson, Myriam Martel, Ron Goeree and F. Stephen Hodi and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Annals of Oncology.

In The Last Decade

Andriy Moshyk

40 papers receiving 310 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Andriy Moshyk United States	12	170	68	57	48	42	50	313
Nikki R. Adler Australia	13	180 1.1×	124 1.8×	61 1.1×	23 0.5×	10 0.2×	31	389
Tina Seto United States	12	170 1.0×	77 1.1×	35 0.6×	16 0.3×	37 0.9×	26	435
Siqi Dai China	11	77 0.5×	131 1.9×	49 0.9×	39 0.8×	11 0.3×	21	330
Rachel Dear Australia	12	229 1.3×	57 0.8×	22 0.4×	15 0.3×	33 0.8×	31	474
Miao Liu China	11	124 0.7×	169 2.5×	49 0.9×	35 0.7×	45 1.1×	33	420
A.L. Vataire France	13	157 0.9×	68 1.0×	50 0.9×	21 0.4×	114 2.7×	34	478
Ana‐Maria Forsea Romania	10	367 2.2×	100 1.5×	158 2.8×	38 0.8×	33 0.8×	29	580
Mitchell S. von Itzstein United States	11	222 1.3×	42 0.6×	45 0.8×	60 1.3×	15 0.4×	32	344
Sarah Jo Stephens United States	9	125 0.7×	93 1.4×	39 0.7×	14 0.3×	18 0.4×	29	387
Giulia Fornasier Italy	9	134 0.8×	51 0.8×	24 0.4×	78 1.6×	38 0.9×	14	413

Countries citing papers authored by Andriy Moshyk

Since Specialization

Citations

This map shows the geographic impact of Andriy Moshyk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andriy Moshyk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andriy Moshyk more than expected).

Fields of papers citing papers by Andriy Moshyk

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andriy Moshyk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andriy Moshyk. The network helps show where Andriy Moshyk may publish in the future.

Co-authorship network of co-authors of Andriy Moshyk

This figure shows the co-authorship network connecting the top 25 collaborators of Andriy Moshyk. A scholar is included among the top collaborators of Andriy Moshyk based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andriy Moshyk. Andriy Moshyk is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Regan, Meredith M., Paolo A. Ascierto, Evan J. Lipson, et al.. (2025). Analysis of treatment-free survival of patients with advanced melanoma receiving nivolumab as monotherapy or in combination with relatlimab in RELATIVITY-047. Journal for ImmunoTherapy of Cancer. 13(9). e012747–e012747.

Long, Georgina V., Evan J. Lipson, F. Stephen Hodi, et al.. (2024). First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data. Journal of Clinical Oncology. 42(33). 3926–3934. 20 indexed citations

Cella, David, Don Husereau, Bellinda L. King‐Kallimanis, et al.. (2024). Administering selected subscales of patient-reported outcome questionnaires to reduce patient burden and increase relevance: a position statement on a modular approach. Quality of Life Research. 33(4). 1075–1084. 3 indexed citations

Ejzykowicz, Flavia, et al.. (2023). CO59 Matching-Adjusted Indirect Comparison (MAIC) of Nivolumab + Relatlimab (NIVO+RELA) Vs. BRAF/MEK Inhibitors for First-Line Treatment of BRAF-Mutant Advanced/Metastatic Melanoma (AMEL). Value in Health. 26(12). S24–S25.

Schadendorf, Dirk, Hussein A. Tawbi, Evan J. Lipson, et al.. (2023). Health-related quality of life with nivolumab plus relatlimab versus nivolumab monotherapy in patients with previously untreated unresectable or metastatic melanoma: RELATIVITY-047 trial. European Journal of Cancer. 187. 164–173. 9 indexed citations

Samlowski, Wolfram E., Nicholas J. Robert, Liwei Chen, et al.. (2022). Real‐World nivolumab dosing patterns and safety outcomes in patients receiving adjuvant therapy for melanoma. Cancer Medicine. 12(3). 2378–2388. 3 indexed citations

Goring, Sarah, et al.. (2022). POSC308 Network Meta-Analysis Under Survival Heterogeneity with Long-Term Survival: A Case Study from Adjuvant Treatment of Resected Stage III/IV Melanoma. Value in Health. 25(1). S208–S208. 1 indexed citations

Kurt, Murat, et al.. (2022). P47 A Bayesian Hierarchical Mixture Cure Modelling (MCM) Framework for the Joint Utilization of Progression Free Survival (PFS) and Overall Survival (OS) in Estimating Long-Term Survivorship Rates in Previously Untreated Metastatic Melanoma: A Case Study from CheckMate-067 Trial. Value in Health. 25(1). S10–S11. 1 indexed citations

Weber, Jeffrey S., Paolo A. Ascierto, Mark R. Middleton, et al.. (2021). Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for resected melanoma. European Journal of Cancer. 158. 225–233. 12 indexed citations

10.

Sofeu, Casimir Ledoux, Anne-Françoise Gaudin, Murat Kurt, et al.. (2021). Time to next treatment or death as a candidate surrogate endpoint for overall survival in advanced melanoma patients treated with immune checkpoint inhibitors: an insight from the phase III CheckMate 067 trial. ESMO Open. 7(1). 100340–100340. 12 indexed citations

11.

Tarhini, Ahmad A., Karmela K Chan, David F. McDermott, et al.. (2021). A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma☆. ESMO Open. 6(2). 100050–100050. 12 indexed citations

12.

Dalle, Stéphane, Laurent Mortier, Pippa Corrie, et al.. (2021). Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study. BMC Cancer. 21(1). 642–642. 12 indexed citations

13.

Suciu, Stefan, Pierre Squifflet, Everardo D. Saad, et al.. (2020). Evaluating the potential of relapse-free survival as a surrogate for overall survival in the adjuvant therapy of melanoma with checkpoint inhibitors. European Journal of Cancer. 137. 171–174. 11 indexed citations

14.

Moshyk, Andriy, et al.. (2019). PCN245 GRADE 3/4 ADVERSE EVENT (AE) COSTS OF NIVOLUMAB VERSUS DABRAFENIB + TRAMETINIB AS ADJUVANT TREATMENT IN PATIENTS WITH STAGE III BRAF-MUTATED CUTANEOUS MELANOMA IN PORTUGAL. Value in Health. 22. S483–S483. 1 indexed citations

15.

Goring, Sarah, Keith Chan, Shannon Cope, et al.. (2019). PCN440 NETWORK META-ANALYSIS USING FRACTIONAL POLYNOMIALS: HEURISTIC FOR MODEL SELECTION INCORPORATING BEYOND-TRIAL EXTRAPOLATIONS (A MELANOMA EXAMPLE). Value in Health. 22. S521–S521. 1 indexed citations

16.

Byrne, Katherine, et al.. (2019). Real-World Systemic Therapy Treatment Patterns for Squamous Cell Carcinoma of the Head and Neck in Canada. Current Oncology. 26(2). 167–174. 9 indexed citations

17.

Le, Hoa H., et al.. (2016). Clinical and economic benefits of extended treatment with apixaban for the treatment and prevention of recurrent venous thromboembolism in Canada. Journal of Medical Economics. 19(6). 557–567. 9 indexed citations

18.

Moshyk, Andriy, et al.. (2016). Risk Share Agreements (RSA), Product Listing Agreements (PLA) or Patient Access Schemes (PAS) - All the Same or Different ?. Value in Health. 19(7). A894–A894. 1 indexed citations

19.

Grant, Andrew, Andriy Moshyk, Hassan Mahmoud Diab, et al.. (2005). Integrating feedback from a clinical data warehouse into practice organisation. International Journal of Medical Informatics. 75(3-4). 232–239. 36 indexed citations

20.

Moshyk, Andriy, et al.. (2005). When is bioavailable testosterone a redundant test in the diagnosis of hypogonadism in men?. Clinical Biochemistry. 38(9). 813–818. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact